UMLS. CSP-HL7-ICD9CM-NCI-NDFRT-RXNORM
%
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
R R R- R0 R1 R2 R3 R4 RA RB RC RD RE RF RG RH RI RK RM RN RO RP RQ RR RS RT RU RV RW RX RY
RE RE- REA REB REC RED REE REF REG REH REI REJ REL REM REN REO REP REQ RER RES RET REU REV REW REX
selected terms: 1,626 page 1 of 17

1. (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide
[A sulfonamide and carbonic anhydrase inhibitor with specific affinity for carbonic anhydrase II. Following topical ocular administration, brinzolamide inhibits carbonic anhydrase II, an enzyme that is responsible for the movement of sodium and fluid transport in the eye. This inhibition leads to a decrease in aqueous humor secretion, probably by slowing the formation of bicarbonate ions, and results in a reduction in intraocular pressure. Brindazolamide is used to treat increased pressure in the eye caused by open-angle glaucoma. ( NCI )] (UMLS (NCI) C0673966) =Organic Chemical; Pharmacologic Substance =azopt;
[OP104] CARBONIC ANHYDRASE INHIBITORS, SYSTEMIC OPHTHALMIC =BRINZOLAMIDE 1 %;
51. Rebeccamycin Analogue, Tartrate Salt
(UMLS (NCI) C1328676) =Organic Chemical; Pharmacologic Substance
2. *Reciprocal Relative Time
(UMLS (HL7) C1547038) =Quantitative Concept =Kind of quantity;
52. Rebetol
(UMLS (NCI) C1170576) =Nucleic Acid, Nucleoside, or Nucleotide; Pharmacologic Substance ;
3. *Relative
(UMLS (HL7) C1547039) =Quantitative Concept =Kind of quantity;
53. Rebif
(UMLS (NCI) C0752980) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
4. *Relative Density
(UMLS (HL7) C1576416) =Qualitative Concept =Kind of quantity;
54. Rebreather Mask*
(UMLS (HL7) C0694641) =Spatial Concept =drug administration route;
5. *Relative Mass Concentration
(UMLS (HL7) C1264645) =Quantitative Concept =Kind of quantity;
55. REC BIL FEM HERN W OBSTR
[ ] (UMLS (ICD9CM) C0156132) =Disease or Syndrome; Anatomical Abnormality
6. *Relative Substance Concentration
(UMLS (HL7) C1264647) =Quantitative Concept =Kind of quantity;
56. REC UNIL FEM HERN W GANG
[ ] (UMLS (ICD9CM) C0156116) =Acquired Abnormality; Disease or Syndrome
7. *Relative Time
(UMLS (HL7) C1547040) =Quantitative Concept =Kind of quantity;
57. REC UNIL FEM HERN W OBST
[ ] (UMLS (ICD9CM) C0156130) =Acquired Abnormality; Disease or Syndrome
8. 186Re-Etidronate
[A synthetic compound containing the radioisotope rhenium 186 and a chelator, hydroxyethylidene diphosphonate (HEDP). Re-HEDP functions as a bone-seeking radiopharmaceutical when it is mixed with bioactive material, hydroxyapatite (calcium phosphate ceramic) via intravenous infusion. Re-186 is a beta emitter, with a short half life, which provides local effects with limited distribution to extramedullary bone marrow tissues. Re-HEDP can be used to treat pain associated with primary and metastatic bone lesions. ( NCI )] (UMLS (NCI) C0280809) =Organophosphorus Compound; Pharmacologic Substance
58. recA protein
[A family of recombinases initially identified in BACTERIA. They catalyze the ATP-driven exchange of DNA strands in GENETIC RECOMBINATION. The product of the reaction consists of a duplex and a displaced single-stranded loop, which has the shape of the letter D and is therefore called a D-loop structure. ( MSH )] (UMLS (CSP) C0034767) =Amino Acid, Peptide, or Protein; Enzyme ;
9. RE
[An Southern Africa, occupying an island in the Indian Ocean, east of Madagascar. (NCI) ( NCI )] (UMLS (NCI) C0035373) =Geographic Area ;
59. Recalcification
[The addition of calcium back to a specimen after it was removed by chelating agents ( HL7V3.0 )] (UMLS (HL7) C1551379) =Intellectual Product =ActSpecimenTreatmentCode;
10. Re-186
[A radioisotope with an atomic number of 75 and a half life of 90 hours that emits beta particles and gamma rays and is used in cancer treatment and diagnostic imaging technique. (NCI) ( NCI )] (UMLS (NCI) C0361302) =Indicator, Reagent, or Diagnostic Aid; Element, Ion, or Isotope ;
60. Recalification
(UMLS (HL7) C1550108) =Therapeutic or Preventive Procedure =Therapeutic Interventions;
11. Re-admission
(UMLS (HL7) C1548168) =Idea or Concept =Re-Admission Indicator;
61. Received into inventory (for specified patient)
(UMLS (HL7) C1548989) =Idea or Concept =Blood Product Dispense Status;
12. Re-Admission Indicator
(UMLS (HL7) C1550376) =Qualitative Concept =HL7 Vocabulary Version 2.5;
=Re-admission
62. Received signed
(UMLS (HL7) C1553448) =Idea or Concept =LanguageAbilityMode;
13. RE-ENTRY OPERATION
[ ] (UMLS (ICD9CM) C0190368) =Therapeutic or Preventive Procedure
63. Received spoken
(UMLS (HL7) C1551045) =Idea or Concept =LanguageAbilityMode;
14. Re-used MET
[This message element type was previously defined in this HMD and is being reused ( HL7V3.0 )] (UMLS (HL7) C1554126) =Idea or Concept =MdfHmdMetSourceType;
64. Received written
(UMLS (HL7) C1551046) =Idea or Concept =LanguageAbilityMode;
15. Reaction
[A response generated by a stimulus. ( NCI )] (UMLS (NCI) C0443286) =Functional Concept
65. receiver
[The person (or organization) who receives the product of an Act. ( HL7V3.0 )] (UMLS (HL7) C1551356) =Idea or Concept =indirect target;
◊ [The entity is the receiver of the transmission. ( HL7V3.0 )] (UMLS (HL7) C1553422) Idea or Concept CommunicationFunctionType;
16. Reaction Alert
[Proposed therapy may be inappropriate or contraindicated based on the potential for a patient reaction to the proposed product ( HL7V3.0 )] (UMLS (HL7) C1553540) =Intellectual Product =Observation Alert;
=Intolerance Alert;
Allergy Alert
66. Receiver responsibility
[This property holds the identifier of the follow-on interaction, when the receiving application role for an interaction has the responsibility to initiate a follow-on interaction. ( HL7V3.0 )] (UMLS (HL7) C1554146) =Idea or Concept =HL7DefinedRoseProperty;
17. reaction rate
[ ] (UMLS (CSP) C0678608) =Temporal Concept
67. Recent
[Near to or not long before the present. ( NCI )] (UMLS (NCI) C0332185) =Temporal Concept
18. reaction rate (chemical)
[ ] (UMLS (CSP) C0598136) =Phenomenon or Process
68. RECENT DETACHMENT, TOTAL
[ ] (UMLS (ICD9CM) C0154813) =Disease or Syndrome ;
19. Reaction to Bacterial Contamination
(UMLS (HL7) C1549010) =Pathologic Function =Transfusion Adverse Reaction;
69. Receptor
[A molecule inside or on the surface of a cell that binds to a specific substance and causes a specific physiologic effect in the cell. ( NCI )] (UMLS (NCI) C0597357) =Amino Acid, Peptide, or Protein; Receptor =binding protein;
=hormone receptor;
drug receptor;
Cell Surface Receptor;
antibody receptor;
leukocyte adhesion molecule;
Cytoplasmic Receptor;
carbohydrate receptor;
nonvisual photoreceptor;
vitamin receptor
20. ReactionActionTaken
[Code used to indicate the action taken by practitioner in response to the problem (whether drug or device related) that is reported in the ICSR. Examples include: failing device replaced, medication stopped, medication dose adjusted. ( HL7V3.0 )] (UMLS (HL7) C1696160) =Clinical Attribute =Individual Case Safety Report Value Domains;
70. Receptor (TNFRSF)-Interacting Serine-Threonine Kinase 1 Gene
[This gene plays a role in apoptosis and signal transduction. ( NCI )] (UMLS (NCI) C1335623) RIPK1;
RIPK1 Gene =Gene or Genome ;
21. Reactivate deactivated record
(UMLS (HL7) C1549605) =Intellectual Product =Record-level event code;
71. receptor activation
[Receptor Activation typically involves a high-affinity binding interaction of a signaling molecule (ligand) with a specific target protein causing a conformational and functional change in the receptor molecule. Altered interaction of the ligand-bound receptor with target molecules leads in turn to changes in cellular physiology through modification of the activity of one or more signal transduction pathways. ( NCI )] (UMLS (CSP) C1514758) =Cell Function
22. REACTIVE CONFUSION
(UMLS (ICD9CM) C0152124) =Mental or Behavioral Dysfunction ;
72. receptor binding
[Receptor Binding involves a temporary non-covalent, typically highly specific and high affinity, interaction through intermolecular physical forces of attraction and spatial complementarity with a diverse group of intrinsic membrane or cytoplasmic proteins that mediate the biological effects of secreted regulatory signaling molecules through modification of the activity of signal transduction pathways. ( NCI )] (UMLS (CSP) C0597358) =Molecular Function ;
=protein binding;
23. Reactive Cutaneous Fibrous Lesion
(UMLS (NCI) C1335666) =Disease or Syndrome ;
73. receptor coupling
[process by which ligand-receptor complex, usually extracellular, effects intracellular events; e.g., via enzyme activity of intracellular domain of receptor protein, or via G protein interactions with other membrane proteins such as ion channels or adenylate cyclase. ( CSP )] (UMLS (CSP) C0597359) =Molecular Function ;
=Signal Transduction;
24. reactive depression
[Depression precipitated by events in a person's life. ( NCI )] (UMLS (CSP) C0011579) =Mental or Behavioral Dysfunction
74. receptor density
[ ] (UMLS (CSP) C0599283) =Genetic Function
25. reactive hyperemia
[excess of blood in a body part following restoration of its temporarily arrested flow. ( CSP )] (UMLS (CSP) C0178824) =Pathologic Function ;
=blood circulation;
75. Receptor Down Regulation
[Due to internalization of ligand-receptor complexes, increased receptor turnover, or decreased receptor expression following exposure to a ligand or agent, Receptor Down Regulation involves a decrease in the number of ligand-specific cellular proteins that bind to, and mediate, the effects of a regulatory molecule. ( NCI )] (UMLS (NCI) C0949469) receptor downregulation =Molecular Function ;
26. Reactive Lymphocytosis
(UMLS (NCI) C1335667) =Disease or Syndrome ;
76. receptor expression
[process by which functional receptors appear, migrate, and disappear at the cell surface; involves gene expression, protein biosynthesis, posttranslational modification, membrane transport, and degradation; can be used to index interspecies receptor gene implants. ( CSP )] (UMLS (CSP) C0597360) =Genetic Function ;
=Expressed;
27. reactive oxygen intermediate
[ ] (UMLS (CSP) C0920643) =Biologically Active Substance ;
77. receptor function
[ ] (UMLS (CSP) C0920644) =Molecular Function ;
28. reactive psychotic depression
[ ] (UMLS (CSP) C0011580) =Mental or Behavioral Dysfunction
78. Receptor Gene
[Receptor Genes encode cell surface or cytoplasmic receptor proteins that each bind to specific signaling factors (such as a hormone, antigen, or neurotransmitter) causing a conformational and functional change in the ligand-bound receptor, altering its interaction with target molecules and leading to changes in cellular physiology through modification of the activity of one or more signal transduction pathways. ( NCI )] (UMLS (NCI) C1335671) =Gene or Genome ;
29. reactive site (enzyme)
[ ] (UMLS (CSP) C0597752) =Functional Concept ;
79. receptor internalization
[The process by which cell surface receptors are monoubiquitinated following ligand-induced activation, and subsequently taken up into endocytic vesicles and targeted to the lysosome or vacuole for degradation; serves as a mechanism to downregulate receptor signaling. [GOC:mah, PMID:15006537] ( GO )] (UMLS (CSP) C0599281) =Phenomenon or Process
30. Read
[to examine and attempt to comprehend the meaning of written or printed characters, words, or sentences; includes reading Braille. ( CSP )] (UMLS (NCI) C0034754) =Daily or Recreational Activity =communication behavior;
Language Ability
80. receptor mediated endocytosis
[pathway for taking up substances which first bind to specific cell surface receptors in coated pits and are then internalized by endocytosis; also internalizes obsolete cell surface receptors. ( CSP )] (UMLS (CSP) C0597361) =Cell Function ;
=endocytosis;
=dephosphin
31. Read Classification
[The Read Clinical Classification of Medicine, Park View Surgery, 26 Leicester Rd., Loughborough LE11 2AG (includes drug procedure and other codes, as well as diagnostic codes). ( HL7V3.0 )] (UMLS (HL7) C1547163) =Intellectual Product =Code;
CodeSystem
81. Receptor Protein-Tyrosine Kinase
[A class of membrane receptors that contain protein tyrosine kinase activity. This enzymatic activity is integral to the function of the receptor as a signal transducer; the phosphorylation event alters the functional activity of its protein substrate. ( NCI )] (UMLS (NCI) C0206364) =Amino Acid, Peptide, or Protein; Enzyme; Receptor
32. reading disorder diagnosis
[ ] (UMLS (CSP) C0872258) =Diagnostic Procedure ;
82. receptor recycling
[The process by which receptor molecules are returned to an active state and in an active cellular location after they have been stimulated by a ligand. An active state is when the receptor is ready to receive a signal. [GOC:dph] ( GO )] (UMLS (CSP) C0599282) =Cell Function
33. Readministration
[The repeated act of the dispensing, applying, or tendering of something to another after an initial treatment. ( NCI )] (UMLS (NCI) C0376495) =Therapeutic or Preventive Procedure
83. receptor sensitivity
[parameter which is increased by agonists and decreased by antagonists, usually measured as the effective dose of ligand for binding or physiological endpoint. ( CSP )] (UMLS (CSP) C0597362) =Functional Concept ;
=Pharmacologic;
34. Reagan Lowe Medium
(UMLS (HL7) C1550085) =Biomedical or Dental Material ;
=Additive/Preservative;
84. Receptor Serine/Threonine Kinase
[Encoded by Receptor Serine/Threonine Kinase Genes, Receptor Serine/Threonine Kinases bind to specific signaling factors causing a conformational and functional change in the ligand-bound receptor, altering its interaction with target molecules, increasing the receptor kinase activity, and leading to changes in cellular physiology through modification of the activity of one or more signal transduction pathways. ( NCI )] (UMLS (NCI) C0219806) =Amino Acid, Peptide, or Protein; Enzyme; Receptor
35. Reagan Lowe Medium
[A transport medium formulated to maintain Bordetella pertussis viability. ( HL7V3.0 )] (UMLS (HL7) C1561486) =Intellectual Product =MaterialEntityAdditive;
85. Receptor Serine/Threonine Kinase Gene
[Receptor Serine/Threonine Kinase Genes encode receptor proteins that each bind to specific signaling factors causing a conformational and functional change in the ligand-bound receptor, altering its interaction with target molecules, increasing the receptor kinase activity, and leading to changes in cellular physiology through modification of the activity of one or more signal transduction pathways. ( NCI )] (UMLS (NCI) C1335672) =Gene or Genome ;
36. Reagent
[A chemical that has general laboratory application and that is not labeled or otherwise intended for a specific application. General purpose reagents include cytological preservatives, decalcifying reagents, fixatives and adhesives, tissue processing reagents, isotonic solutions, and pH buffers. ( NCI )] (UMLS (NCI) C0034760) =Indicator, Reagent, or Diagnostic Aid
86. receptor structure function
[ ] (UMLS (CSP) C0599221) =Chemical Viewed Functionally
37. Reagent Calibrator
(UMLS (HL7) C1550148) =Indicator, Reagent, or Diagnostic Aid =Substance type;
87. Receptor Tyrosine Kinase Gene
[Tyrosine kinase receptors (TRKs) are a family of genes encoding neurotrophin receptors that include trkA, trkB, and trkC, which are related to development, differentiation, and survival of neural crest-derived neurons and central cholinergic neurons in normal tissue. The genes encoding trkA, trkB, and trkC are designated NTRK1, NTRK2, and NTRK3 and map to chromosomes 1, 9, and 15, respectively. A member of the TRK gene family, trkE, encodes a non-neuronal receptor for nerve growth factor. (from OMIM 600408) ( NCI )] (UMLS (NCI) C1335675) =Gene or Genome ;
38. reagent standard
[ ] (UMLS (CSP) C1328942) =Intellectual Product ;
88. Receptor Tyrosine Kinase-Like Orphan Receptor 1 Gene
[This gene is thought to play a role in skeletal and cardiac development, but an exact function has yet to be determined. ( NCI )] (UMLS (NCI) C1335633) ROR1;
ROR1 Gene =Gene or Genome ;
39. reagent standardization
[ ] (UMLS (CSP) C1328943) =Intellectual Product ;
89. Receptor Tyrosine Kinase-Like Orphan Receptor 2 Gene
[This gene plays a role in early chondrocyte formation, cartilage formation and growth plate development. Mutations in the gene are associated with skeletal disorders. ( NCI )] (UMLS (NCI) C1366544) ROR2;
ROR2 Gene =Gene or Genome
40. reagent testing
[ ] (UMLS (CSP) C1328944) =Research Activity ;
90. receptor upregulation
[A positive regulatory process that increases ligand-receptor interactions. Increase in receptor binding after ligand exposure can result from receptor activation, aggregation, increase in half-life, and/or an increase in gene expression that leads to de novo receptor synthesis. ( MSH )] (UMLS (CSP) C0949479) =Cell Function; Molecular Function
41. reagent/indicator
[substance employed to produce a chemical reaction so as to detect, measure, or produce other substances. ( CSP )] (UMLS (CSP) C0021213) =Indicator, Reagent, or Diagnostic Aid ;
=Chemical;
=acid;
Alkylating Activity;
buffer;
chelating agent;
Contrast Agent;
culture media;
detergent;
dye;
molecular probe;
sulfhydryl reagent;
electron acceptor;
catalyst;
base;
reducing agent;
acylating agent;
calcium indicator;
radiolabel
91. Receptor, Vascular Endothelial Growth Factor
[There are three signaling VEGF receptors. The VEGF family members PIGF and VEGF-B with exclusive binding capacities to the VEGFR-1 can influence monocyte activation and differentiation. The VEGFR-2 and VEGFR-3 binding VEGF homologues, VEGF-C and VEGF-D, are mitogens for both vascular and lymphatic endothelial cells. The orf virus encoded VEGF-E homologue binds and activates only the VEGFR-2 and thus may be the prototype of a vascular endothelial cell-specific growth factor. Further specific activities of VEGF and its homologues result from receptor-specific signaling and differential expression of ligands or receptors. A naturally occurring soluble form of the VEGFR-1 suggests a regulatory role for this receptor. ( NCI )] (UMLS (NCI) C0148199) =Amino Acid, Peptide, or Protein; Enzyme; Receptor
42. Real Time
[Query response to occur in real time. ( HL7V3.0 )] (UMLS (HL7) C1550177) =Idea or Concept =Response modality;
ResponseModality
92. Receptor-Interacting Protein
[A 74 kDa serine/threonine kinase originally identified by its ability to associate with Fas/APO-1 and induce cell death. RIP interacts with the cytoplasmic domain of FAS, and with TNFR1 through the adaptor proteins TRADD and TRAFs 1, 2, and 3. ( NCI )] (UMLS (NCI) C0297981) =Amino Acid, Peptide, or Protein; Enzyme
43. real time model
[ ] (UMLS (CSP) C0872363) =Intellectual Product ;
93. Receptor-Interacting Serine-Threonine Kinase 2 Gene
[This gene is involved in apoptosis, signal transduction and the immune response. ( NCI )] (UMLS (NCI) C1335624) RIPK2;
RIPK2 Gene =Gene or Genome ;
44. RealmOfUse
[The jurisdiction or realm within which the domain will be used. A realm might be a country, a group of countries, a region of the world, or an organization. ( HL7V3.0 )] (UMLS (HL7) C1701906) =Spatial Concept ;
=VocabularyDomainQualifier;
=CA;
North America;
UNITED STATES;
Universal;
94. Receptor-Interacting Serine-Threonine Kinase 3 Gene
[This gene plays a role in signal transduction and the activation of apoptosis. ( NCI )] (UMLS (NCI) C1335625) RIPK3;
RIPK3 Gene =Gene or Genome ;
45. Reanastomosis of urethra
[ ] (UMLS (ICD9CM) C0194643) =Therapeutic or Preventive Procedure
95. Recession of chamber angle of eye
[ ] (UMLS (ICD9CM) C0154937) =Pathologic Function ;
46. REASON FOR CONSULT NOS
[ ] (UMLS (ICD9CM) C0041880) =Finding ;
96. Recession of tendon
[ ] (UMLS (ICD9CM) C0185466) =Therapeutic or Preventive Procedure
47. ReasonForNotEvaluatingDevice
[Code assigned to indicate the rationale for not performing an evaluation investigation on a device for which a defect has been reported. Examples include: device received in a condition that made analysis impossible, device evaluation anticipated but not yet begun, device not made by company. ( HL7V3.0 )] (UMLS (HL7) C1696161) =Intellectual Product =ActReason;
97. Reciprocal Translocation
(UMLS (NCI) C0333714) =Cell or Molecular Dysfunction ;
48. REATTACH AMPUTATED EAR
[ ] (UMLS (ICD9CM) C0395659) =Therapeutic or Preventive Procedure
98. RECLOSE POST OP DISRUPT
(UMLS (ICD9CM) C0198546) =Therapeutic or Preventive Procedure
49. Reattachment of extremity
[ ] (UMLS (ICD9CM) C0408884) =Therapeutic or Preventive Procedure
99. Recombinant Antibodies
[Antibodies produced by recombinant DNA techniques. ( NCI )] (UMLS (NCI) C1335676) Recombinant Antibody;
=Amino Acid, Peptide, or Protein; Immunologic Factor
50. Reattachment of tendon
[ ] (UMLS (ICD9CM) C0185398) =Therapeutic or Preventive Procedure
100. Recombinant Fowlpox Tyrosinase
[A recombinant fowlpox virus vaccine with potential antineoplastic activity. Binding to the melanoma antigen tyrosinase, recombinant fowlpox-tyrosinase vaccine generates cellular immune responses against melanoma cells expressing the tyrosinase antigen; this effect is enhanced by the co-administration of interleukin 2 (IL-2). Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells. ( NCI )] (UMLS (NCI) C1327884) Recombinant Fowlpox-Tyrosinase Vaccine;
rF-TYR;
rF-TYR vaccine;
Tyrosinase-Fowl Pox =Pharmacologic Substance; Immunologic Factor

Buy website

Medical Clinic. Optician. Pharmacy. Physician. Travel Agency. Hotel reservation. Child Care. Education. Teachers. Lessons. Tests and Exams. Certification. Shopping Center. Store. Real Estate.
Affordable prices from $100.


 home Dictionaries Armenian-English English-Armenian MeSH Feedback  top
© 2008 -2011 Administrator MEDINDEX.AM